Drug Information

Drug (ID: DG00524) and It's Reported Resistant Information

• Name: Bamlanivimab
• Synonyms: LY-CoV555; LY3819253
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  COVID-19 [ICD-11: 1D92]; [1]
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Severe Acute Respiratory Syndrome coronavirus [ICD-11: XN1V8]; [2]
• Formula: C6498H10068N1732O2032S46
• DrugBank ID: DB15718

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

COVID-19 [ICD-11: 1D92]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Moesin (MSN) [1]

• Resistant Disease: Corona Virus Disease 2019 [ICD-11: 1D92.0]
• Molecule Alteration: Mutations; E340K
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Hela cells; Cervix uteri; Homo sapiens (Human); CVCL_0030
• In Vitro Model: Vero E6 cells; Kideny; Homo sapiens (Human); N.A.
• In Vitro Model: BHKG43 cells; Kideny; Homo sapiens (Human); N.A.
• In Vitro Model: HEK 293T cells; Kidney; Homo sapiens (Human); CVCL_0063
• Experiment for Molecule Alteration: qRT-PCR; Deep sequencing assay
• Experiment for Drug Resistance: Immunofluorescence assay
• Mechanism Description: Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 are effective against COVID-19 and might mitigate future pandemics. However, their efficacy is challenged by the emergence of antibody-resistant virus variants.

ICD-X: Extension Codes

Severe Acute Respiratory Syndrome coronavirus [ICD-11: XN1V8]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Spike glycoprotein (S) [2]

• Resistant Disease: severe acute respiratory syndrome coronavirus 2 [ICD-11: XN1V8]
• Molecule Alteration: Mutation; .
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: Patient-derived allogeneic stem cell transplant model; Homo sapiens
• Mechanism Description: We report the case of an allogeneic stem cell transplant recipient with nosocomial acquisition of SARS-CoV-2 infection who received antispike neutralizing monoclonal antibody bamlanivimab 2 days after diagnosis of SARS-CoV-2 infection but progressed to severe COVID-19 pneumonia and died with the selection of E484K/Q resistance mutations to bamlanivimab.

References

• Ref 1: Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis. Antiviral Res. 2024 Nov;231:106006.
• Ref 2: Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection. Antivir Ther. 2024 Feb;29(1):13596535221097495.